ArticleScientific reports2015
Tetranectin as a Potential Biomarker for Stable Coronary Artery Disease.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Diagnostic and Prognostic Potential of Tetranectin in Heart Failure and Cardiovascular Disease: A Systematic Review.Medical sciences (Basel, Switzerland) · 2025Pooled it
- A validated, modifiable proteomic score from the EXSCEL trial predicts cardiovascular events in diabetes.JCI insight · 2026Trial
- Tetranectin as a Potential Biomarker Associated with Post-Operative Inotropic Support Following the Norwood Procedure in Neonates: A Pilot Study.Journal of cardiovascular development and disease · 2026Article
- Tetranectin: Molecular Mechanisms, Biological Functions and Clinical Implications.International journal of molecular sciences · 2026Review
- Unveiling the Mysteries of CLEC3B: Physiological Roles, Pathological Impacts, and Research Gaps.Cells · 2026Review
- Proteogenomic Analysis of Coronary Artery Calcification in Human Populations.Arteriosclerosis, thrombosis, and vascular biology · 2026Article
- Tetranectin and Paraoxonase-1 as Markers of Heart Failure.Medicina (Kaunas, Lithuania) · 2026Review
- Pharmacological intervention of the HMGB1-pCTS-L axis to ameliorate inflammatory diseases.Frontiers in immunology · 2026Review
- Tetranectin and Paraoxonase 1 in Patients with Varying Stages of Heart Failure: A Cross-Sectional Analysis.Clinics and practice · 2025Article
- Insight into the function of tetranectin in human diseases: A review and prospects for tetranectin-targeted disease treatment.Heliyon · 2024Review
- Relationship between serum interleukin-6 levels and severity of coronary artery disease undergoing percutaneous coronary intervention.BMC cardiovascular disorders · 2023Article
- Tetranectin as a potential novel prognostic biomarker in anthracycline-related cardiac dysfunction.Heart and vessels · 2023Article
- Proteomic cardiovascular risk assessment in chronic kidney disease.European heart journal · 2023Article
- Article
- The adipocyte-enriched secretory protein tetranectin exacerbates type 2 diabetes by inhibiting insulin secretion from β cells.Science advances · 2022Article
- Serum Proteomic Changes in Dogs with Different Stages of Chronic Heart Failure.Animals : an open access journal from MDPI · 2022Article
- Review
- Association of 71 cardiovascular disease-related plasma proteins with pulmonary function in the community.PloS one · 2022Article
- CD5L as an Extracellular Vesicle-Derived Biomarker for Liquid Biopsy of Lung Cancer.Diagnostics (Basel, Switzerland) · 2021Article
- Advances in Cardiovascular Biomarker Discovery.Biomedicines · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This cross-sectional study tested the hypothesis that decreased serum levels of tetranectin (TN), a regulator of the fibrinolysis and proteolytic system, is associated with the presence and severity of CAD. We conducted a systematic serological and immunohistochemical (IHC) analysis to respectively compare the TN levels in serum and artery samples in CAD patients and healthy controls. Our results showed that serum levels of TN were significantly lower in patients with CAD than in healthy controls. Further analysis via trend tests revealed that serum TN levels correlated with the number of diseased arteries. Besides, the multivariate logistic regression model revealed TN as an independent factor associated with the presence of CAD. Additionally, IHC analysis showed that TN expression was significantly higher in atherosclerotic arteries as compared to healthy control tissues. In conclusion, our study suggests that increased serum TN level is associated with the presence and severity of diseased coronary arteries in patients with stable CAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.